Table 2.
List of symptoms, signs, laboratory parameters, and neurological and disability tests in 366 patients with probable Zika virus infection in Tapachula, Chiapas, Mexico.
| Symptoms, signs, laboratory parametersa | Combined variables for regression trees | Proportion or mean ± SD of | |||
|---|---|---|---|---|---|
|
|
|||||
| All groups | Zika | Dengue | UAI | ||
|
| |||||
| Malaise/fatigue (1) | Malaise/Myalgia | 0.98 | 0.91 | 0.98 | 0.99 |
| Myalgia/muscle pain (1) | 0.89 | 0.91 | 0.9 | 0.89 | |
| Arthralgia/joint pain (1) | 0.9 | 0.67 | 0.95 | 0.91 | |
| Headache (1) | 0.9 | 0.82 | 0.95 | 0.91 | |
| Fever (1) | 0.87 | 0.70 | 0.95 | 0.87 | |
| Conjunctivitis (1) | 0.48 | 0.61 | 0.39 | 0.48 | |
| Rash (1) | 0.46 | 0.67 | 0.59 | 0.41 | |
| Myalgia/muscle pain (2) | 0.63 | 0.58 | 0.51 | 0.67 | |
| Myoarthralgia/back pain (2) | Pain | 0.61 | 0.58 | 0.54 | 0.63 |
| Arthralgia/joint pain (2) | 0.46 | 0.42 | 0.42 | 0.47 | |
| Malaise/fatigue (2) | 0.57 | 0.48 | 0.59 | 0.57 | |
| Photophobia (2) | 0.49 | 0.64 | 0.39 | 0.49 | |
| Sore throat (2) | 0.46 | 0.39 | 0.29 | 0.5 | |
| Cough (2) | 0.45 | 0.27 | 0.32 | 0.5 | |
| Periorbital pain (2) | 0.43 | 0.36 | 0.31 | 0.47 | |
| Difficulty standing (2) | Lack of mobility | 0.41 | 0.36 | 0.49 | 0.4 |
| Difficulty walking (2) | 0.34 | 0.3 | 0.34 | 0.35 | |
| Muscle weakness (2) | 0.33 | 0.27 | 0.34 | 0.34 | |
| Itch (2) | 0.38 | 0.52 | 0.53 | 0.33 | |
| Nausea (2) | Nausea/vomiting | 0.33 | 0.27 | 0.4 | 0.35 |
| Vomiting (2) | 0.09 | 0.06 | 0.1 | 0.09 | |
| Erythematous rash (3) | 0.32 | 0.27 | 0.54 | 0.28 | |
| Localized rash (3) | 0.32 | 0.58 | 0.19 | 0.31 | |
| Generalized rash (3) | 0.16 | 0.09 | 0.47 | 0.1 | |
| Maculopapular rash (3) | 0.13 | 0.36 | 0.08 | 0.11 | |
| Petechiae (3) | 0.07 | 0 | 0.24 | 0.05 | |
| Petechial or purpuric rash (3) | 0.05 | 0.03 | 0.14 | 0.03 | |
| Confusion/disorientation (2) | 0.22 | 0.09 | 0.1 | 0.26 | |
| Behavior alterations (2) | 0.21 | 0.15 | 0.15 | 0.23 | |
| Diarrhea (2) | 0.19 | 0.06 | 0.25 | 0.2 | |
| Stiff neck (2) | 0.18 | 0.12 | 0.2 | 0.19 | |
| Mouth ulcers (2) | 0.15 | 0.09 | 0.14 | 0.16 | |
| Bleeding (2) | 0.05 | 0.03 | 0.05 | 0.05 | |
| Ecchymosis or hematomas (3) | 0.02 | 0.03 | 0.03 | 0.01 | |
| MoCA score (3) | 26.28 (4.01) | 25.30 (3.31) | 26.64 (4.08) | 26.31 (4.07) | |
| WHODAS score (3) | 36.91 (14.65) | 33.13 (15.88) | 42.71 (15.80) | 36.12 (13.96) | |
| ALT IU/μl (3) | 63.77 (63.26) | 47.61 (31.71) | 114.25 (107.33) | 54.85 (46.08) | |
| Leukocyte count cell/ml (3) | 7.14 (3.62) | 6.06 (2.82) | 4.38 (2.31) | 7.86 (3.63) | |
| Neutrophil % (3) | 55.27 (17.13) | 56.76 (12.76) | 40.51 (17.73) | 58.27 (15.82) | |
| Platelet count IU/μl (3) | 220.55 (97.87) | 259.64 (96.22) | 96.36 (61.59) | 242.59 (83.12) | |
ALT, alanine aminotransferase; MoCA, Montreal Cognitive Assessment; SD, standard deviation; UAI, undefined acute illness; WHODAS, World Health Organization Disability Assessment Schedule.
a
(1) Indicates self-reported eligibility symptoms collected 0–7 days after symptom onset. (2) Indicates self-reported symptoms collected 3–10 days after symptom onset. (3) Indicates data collected at physical examination 0–7 days after symptom onset.